CP is the most common cause of chronic disability in childhood occurring in 2–2.5/1000
births. It is a severe disorder and a significant number of patients present cognitive delay …

The aim of this article is to describe our clinical experience in treating muscle imbalance in
49 children with spastic upper extremity involvement. We discuss four cohorts of children …

Objectives In the last 2 decades, BTX-A is increasingly being used in the management of
spasticity in children with Cerebral Palsy (CP) and there is no doubt about its effect on range …

Purpose The purpose of this review is to clarify the role of botulinum toxin serotype A (BTX-
A) in the treatment of children with cerebral palsy (CP), with a special focus on the lower …

Botulinum toxin A (BTX‐A) is increasingly being used in early management of spasticity in
ambulant children with cerebral palsy (CP), with the aim of improving function, promoting …

Spasticity, following the neurological disorder of cerebral palsy (CP), describes a
pathological condition, the central feature of which is involuntary and prolonged muscle …

Spasticity, following the neurological disorder of cerebral palsy (CP), describes a
pathological condition, the central feature of which is involuntary and prolonged muscle …

Injected in a muscle, the botulinum toxin causes localized and temporary paralysis by acting
on the neuromuscular synapse. Currently, it is widely prescribed for the treatment of limb …

Background: Cerebral palsy (CP) is the most common cause of childhood disability globally.
Botulinum toxin A injections are widely used to manage limb spasticity in children with CP …

Introduction Spasticity has been considered to be a main contributor to both the impairment
of function as well as posture in children with cerebral palsy (CP). Patterns of upper limb …